15 drug(s) with this reaction
56,325 total reports
Dyspnoea has been reported as an adverse reaction across 15 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 56,325 adverse event reports mention dyspnoea in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with dyspnoea, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have dyspnoea listed in their FDA adverse event reports, sorted by report count:
In addition to dyspnoea, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
15 drug(s) manufactured by Abbvie Inc have dyspnoea listed in their FDA adverse event reports: LEVOTHYROXINE SODIUM, Humira, ADALIMUMAB, FENOFIBRATE, UPADACITINIB, and others.
There are a combined 56,325 reports of dyspnoea across 15 Abbvie Inc drug(s) in the FDA adverse event database.